Bike the US for ALS – 30th Anniversary Ride
Ride. Support. Make an Impact.
We invite you to join us for a special fundraising ride as we commemorate 30 years of advancing ALS research and care through NEALS.
🚴♂️ September 18–24, 2025
📍 Route: GAP and C&O Trail (Pittsburgh, PA → Washington, D.C.)
🎯 Fundraising Goal: $5,000 per rider
QALSODY™ (tofersen injection) Receives Conditional Marketing Authorization from Health Canada as the First ALS Treatment Targeting a Genetic Cause
The Centers for Medicare & Medicaid Services (CMS) has announced a first-of-its-kind directive requiring Medicare Advantage plans to approve coverage for Qalsody, a treatment for people living with genetic SOD1-ALS. This decision reflects the ALS Association’s commitment to ensuring that people living with ALS have access to promising ALS treatments without delay.
The Access for All in ALS Consortium (ALL ALS) announced the successful enrollment of the first participant..
Established in the autumn of 2023 with funding from the National Institutes of Health (NIH), ALL ALS is a multi-institutional effort, and aims to disrupt the ALS clinical research landscape using open science methods to build broadly accessible resources to advance ALS research. The consortium brings together research scientists from across the country, combining their efforts to collect clinical and biomarker data from people with ALS symptoms, asymptomatic individuals at risk of developing inherited forms of ALS, and control participants. The ALL ALS clinical and genomic data and biofluid collections will help researchers investigate the antecedents of ALS, its onset, progression, prognostication, and response to effective therapies.
Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer’s disease, today announced final results from its Phase 2 study of TPN-101 in patients with amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) related to hexanucleotide repeat expansion in the C9orf72 gene (C9orf72-related ALS/FTD).
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) has contracted with PharmAust Limited to begin designing a regimen in the HEALEY ALS Platform Trial.
